Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies

Abstract

Retinitis pigmentosa (RP) is genetically heterogeneous retinopathy caused by photorecep-tor cell death and retinal pigment epithelial atrophy that eventually results in blindness in bilateral eyes. Various photoreceptor cell death types and pathological phenotypic changes that have been disclosed in RP demand in‐depth research of its pathogenic mechanism that may account for inter-patient heterogeneous responses to mainstream drug treatment. As the primary method for study-ing the genetic characteristics of RP, molecular biology has been widely used in disease diagnosis and clinical trials. Current technology iterations, such as gene therapy, stem cell therapy, and opto-genetics, are advancing towards precise diagnosis and clinical applications. Specifically, technolo-gies, such as effective delivery vectors, CRISPR/Cas9 technology, and iPSC‐based cell transplanta-tion, hasten the pace of personalized precision medicine in RP. The combination of conventional therapy and state‐of‐the‐art medication is promising in revolutionizing RP treatment strategies. This article provides an overview of the latest research on the pathogenesis, diagnosis, and treatment of retinitis pigmentosa, aiming for a convenient reference of what has been achieved so far.